AUTOLUS
LIVE

Serial Number

79420853

Owner

Autolus Limited

Attorney

Rebecca Liebowitz

Filing Date

Jan 27, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AUTOLUS Trademark

Serial Number: 79420853 • Registration: 8097979

AUTOLUS is a trademark filed by Autolus Limited on January 27, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Autolus Limited (7 trademarks)

The MediaWorks

Entity Type: 99

Trademark Details

Filing Date

January 27, 2025

Registration Date

January 13, 2026

Published for Opposition

November 25, 2025

Goods & Services

Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines

Medical and veterinary preparations for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposes, in particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, in particular T cell therapy; vaccines

Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical services, namely, manipulation of human and animal cells for therapeutic purposes; medical services, namely, reinsertion of cells into human and animal patients; medical and veterinary services, namely, providing advice and consultancy in the field of medical and veterinary therapies; medical and veterinary services, namely, providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines

Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services, in particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, in particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 13, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 13, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 27, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 27, 2025 TROA
REFUSAL PROCESSED BY IB
Jul 12, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 21, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jun 21, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 18, 2025 RFCR
NON-FINAL ACTION WRITTEN
Apr 17, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 4, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 3, 2025 REPR